Sensus Healthcare (SRTS) appoints Larry Biscotti as independent Class I director

Rhea-AI Filing Summary

Sensus Healthcare, Inc. reported that its Board of Directors appointed Larry Biscotti as a Class I director on January 5, 2026, with a term running through the company’s annual meeting in 2028. He will receive the same director compensation as other non-employee board members on a pro-rata annual basis.

The company stated that there are no arrangements or understandings with other persons related to his election and that he has no material interest in any transaction requiring disclosure under SEC rules. The Board determined that Mr. Biscotti qualifies as an independent director under Nasdaq listing standards. The company later issued a press release on January 7, 2026, announcing his election.

false 0001494891 0001494891 2026-01-05 2026-01-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2026

SENSUS HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37714		27-1647271
(State of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida				33487
(Address of principal executive offices)				(Zip Code)

Registrant's telephone number, including area code: (561) 922-5808

_________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		SRTS		Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SENSUS HEALTHCARE, INC.

FORM 8-K

CURRENT REPORT

ITEM 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d)

On January 5, 2026, the Board of Directors (the “Board”) of Sensus Healthcare, Inc. (the “Company”) appointed Larry Biscotti as a Class I director of the Company for a term expiring at the Company’s annual meeting in 2028.

There are no arrangements or understandings between Mr. Biscotti and any other persons pursuant to which he was elected, nor does he have any direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Securities and Exchange Commission Regulation S-K. As a director of the Company, Mr. Biscotti is expected to receive the same compensation for service as a director as is provided to other non-employee directors of the Company on a pro-rata annual basis. The Board has determined that Mr. Biscotti is an independent director within the meaning of Rule 5605(a)(2) as set forth in the listing standards of The NASDAQ Stock Market, LLC. At the time of the filing of this Current Report, any committee to which Mr. Biscotti may be appointed has not been determined.

On January 7, 2026, the Company issued a press release announcing Mr. Biscotti’s election. The press release is filed as an exhibit to this Report. The press release shall not be deemed "filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated January 7, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SENSUS HEALTHCARE, INC.
Date:       January 9, 2026	By:	/s/ Javier Rampolla
		Javier Rampolla
		Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release, dated January 7, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

FAQ

What did Sensus Healthcare (SRTS) announce in this 8-K filing?

Sensus Healthcare announced that its Board of Directors appointed Larry Biscotti as a Class I director for a term expiring at the company’s annual meeting in 2028.

Who is the new director appointed to Sensus Healthcare’s board?

The Board of Sensus Healthcare appointed Larry Biscotti as a Class I director, with his term scheduled to expire at the company’s annual meeting in 2028.

Is Larry Biscotti considered an independent director at Sensus Healthcare (SRTS)?

Yes. The Board determined that Larry Biscotti is an independent director under Rule 5605(a)(2) of the Nasdaq Stock Market listing standards.

Are there any special arrangements tied to Larry Biscotti’s election to Sensus Healthcare’s board?

No. The company states there are no arrangements or understandings with any other persons under which Mr. Biscotti was elected and that he has no material interest in related-party transactions requiring disclosure.

How will Larry Biscotti be compensated as a director of Sensus Healthcare?

As a director, Larry Biscotti is expected to receive the same compensation provided to other non-employee directors of Sensus Healthcare, on a pro-rata annual basis.

Has Sensus Healthcare assigned Larry Biscotti to any board committees yet?

At the time of the report, the company stated that any committee assignments for Larry Biscotti had not yet been determined.

Did Sensus Healthcare issue a press release about Larry Biscotti’s election?

Yes. Sensus Healthcare issued a press release on January 7, 2026, announcing Mr. Biscotti’s election, and included it as Exhibit 99.1 to the report.